Cagrilintide

Cagrilintide

Cagrilintide (long-acting amylin analog)

Long-acting amylin analog — appetite control via different pathway than GLP-1

Fat Loss ★ 75
Half-life
~7 days (acyl-modified for once-weekly dosing)
Cycle
Long-term maintenance like GLP-1 drugs. Taper down if discontinuing to avoid rebound appetite.
Storage
Lyophilized: refrigerated 2-8°C. After reconstitution: 2-8°C, 28 days.
Research
Phase 3 monotherapy trials (Novo Nordisk). Expected to file FDA submission 2025-2026 as alternative or addition to semaglutide.

About

Novo Nordisk's long-acting amylin analog. Slows gastric emptying and suppresses appetite via amylin receptors. Studied as monotherapy and as the cagri component of CagriSema.

Mechanism

Selective amylin receptor (AMY1-3) agonist; pancreatic amylin co-secreted with insulin. Slows gastric emptying, suppresses post-meal glucagon, reduces appetite via hindbrain area postrema.

Dosage

0.3 mg
1x per week
0102030405060708090100

Draw to 12 units on a U-100 insulin syringe

5 mg · 2 mL BAC

Route
Subcutaneous (SubQ)
Duration
Titration phase 4 weeks

When to take: Same day each week. Independent of meals.

Reconstitution

Vial size (mg): 5 mg · BAC water (mL): 2 mL · Concentration: 2.5 mg/mL

Compounded version. Clinical product is pre-filled pen.

Benefits

  • 10-12% weight loss as monotherapy in Phase 2
  • Different mechanism than GLP-1 (complementary or alternative)
  • Less nausea than semaglutide
  • Smooth appetite control without 'food noise' crashes
  • Pairs synergistically with semaglutide (see CagriSema)

Side effects

  • Nausea (mild, less than GLP-1)
  • Decreased appetite (intended)
  • Injection-site reactions
  • Hypoglycemia (if combined with other diabetes meds)

Gender notes

Same dose. Studied in mixed-sex Phase 2/3 cohorts.

Cautions

  • Pregnancy and breastfeeding
  • Severe gastroparesis
  • Personal history of pancreatitis
  • Type 1 diabetes (limited data)

Research

Stacks well with

SemaglutideTesamorelinMOTS-c
Add reminder Calculator